William Richard White - 21 Dec 2021 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Financial Officer
Signature
/s/ Jonathan Young, Attorney-in-fact
Issuer symbol
AKRO
Transactions as of
21 Dec 2021
Net transactions value
-$1,499
Form type
4
Filing time
23 Dec 2021, 20:03:59 UTC
Previous filing
20 Dec 2021
Next filing
18 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $701 +100 +3.1% $7.01* 3,377 21 Dec 2021 Direct
transaction AKRO Common Stock Sale $2,200 -100 -3% $22.00 3,277 21 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -100 -0.03% $0.000000 324,029 21 Dec 2021 Common Stock 100 $7.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a Rule 10b5-1 trading plan dated June 2, 2021 previously adopted by the Reporting Person.
F2 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter.